About: Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection
Creator	Drosten, Christian Lattwein, Erik Meyer, Benjamin Sieberg, Andrea Assiri, Abdullah Binger, Tabea Muth, Doreen Albarrak, Ali Almasri, Malak Memish, Ziad Farah, Mohamed Steinhagen, Katja Müller, Marcel Al-Tawfiq, Jaffar Corman, Victor Omrani, Ali Albarrak, Mohammed
Source	Medline; PMC
abstract	Background. The Middle East respiratory syndrome (MERS) coronavirus causes isolated cases and outbreaks of severe respiratory disease. Essential features of the natural history of disease are poorly understood. Methods. We studied 37 adult patients infected with MERS coronavirus for viral load in the lower and upper respiratory tracts (LRT and URT, respectively), blood, stool, and urine. Antibodies and serum neutralizing activities were determined over the course of disease. Results. One hundred ninety-nine LRT samples collected during the 3 weeks following diagnosis yielded virus RNA in 93% of tests. Average (maximum) viral loads were 5 × 10(6) (6 × 10(10)) copies/mL. Viral loads (positive detection frequencies) in 84 URT samples were 1.9 × 10(4) copies/mL (47.6%). Thirty-three percent of all 108 serum samples tested yielded viral RNA. Only 14.6% of stool and 2.4% of urine samples yielded viral RNA. All seroconversions occurred during the first 2 weeks after diagnosis, which corresponds to the second and third week after symptom onset. Immunoglobulin M detection provided no advantage in sensitivity over immunoglobulin G (IgG) detection. All surviving patients, but only slightly more than half of all fatal cases, produced IgG and neutralizing antibodies. The levels of IgG and neutralizing antibodies were weakly and inversely correlated with LRT viral loads. Presence of antibodies did not lead to the elimination of virus from LRT. Conclusions. The timing and intensity of respiratory viral shedding in patients with MERS closely matches that of those with severe acute respiratory syndrome. Blood viral RNA does not seem to be infectious. Extrapulmonary loci of virus replication seem possible. Neutralizing antibodies do not suffice to clear the infection.
has issue date	2016-02-15(xsd:dateTime)
bibo:doi	10.1093/cid/civ951
bibo:pmid	26565003
has license	no-cc
sha1sum (hex)	5de523fd2c5ec10034fafb33fd192fcde1a28973
schema:url	https://doi.org/10.1093/cid/civ951
resource representing a document's title	Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection
has PubMed Central identifier	PMC7108065
has PubMed identifier	26565003
schema:publication	Clin Infect Dis
resource representing a document's body	covid:5de523fd2c5ec10034fafb33fd192fcde1a28973#body_text
is schema:about of	named entity 'The Middle' named entity 'CLINICAL' named entity 'RESPIRATORY DISEASE' named entity 'CAUSES' named entity 'ISOLATED CASES' named entity 'OUTBREAKS' named entity 'SEVERE' named entity 'PATIENTS' named entity 'ANTIBODY RESPONSE' covid:arg/5de523fd2c5ec10034fafb33fd192fcde1a28973 named entity 'DISEASES VIRAL' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'CORONAVIRUS INFECTION' named entity 'VIRAL SHEDDING' named entity 'FEATURES' named entity 'BACKGROUND' named entity 'POORLY' named entity 'UNDERSTOOD' named entity 'ESSENTIAL' named entity 'INFECTIOUS DISEASES' named entity 'MIDDLE EAST RESPIRATORY SYNDROME ' named entity 'CORONAVIRUS' named entity 'NATURAL HISTORY OF DISEASE' named entity '8 days' named entity 'antibodies' named entity 'serum' named entity 'mononuclear cells' named entity 'LRT' named entity 'RNA' named entity 'epidemic' named entity 'Germany' named entity 'type I interferon' named entity 'MERS' named entity 'immunoglobulin' named entity 'seroconverted' named entity 'viremia' named entity 'serum' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'dendritic cells' named entity 'excretion' named entity 'IgM' named entity 'viral RNA' named entity 'upper respiratory tract' named entity 'virological' named entity 'virus isolation' named entity 'linear correlation' named entity 'Hong Kong' named entity 'neutralization tests' named entity 'MERS-CoV' named entity 'serum' named entity 'Viremia' named entity 'serum samples' named entity 'MERS' named entity 'infection' named entity 'antibody' named entity 'MERS' named entity 'spike protein' named entity 'respiratory tract' named entity 'kidney cells' named entity 'kidney' named entity 'IgG' named entity 'CaCo2' named entity 'Infection' named entity 'Middle East Respiratory Syndrome Coronavirus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software